Utility of telomerase-pot1 fusion protein in vascular tissue engineering.


While advances in regenerative medicine and vascular tissue engineering have been substantial in recent years, important stumbling blocks remain. In particular, the limited life span of differentiated cells that are harvested from elderly human donors is an important limitation in many areas of regenerative medicine. Recently, a mutant of the human telomerase reverse transcriptase enzyme (TERT) was described, which is highly processive and elongates telomeres more rapidly than conventional telomerase. This mutant, called pot1-TERT, is a chimeric fusion between the DNA binding protein pot1 and TERT. Because pot1-TERT is highly processive, it is possible that transient delivery of this transgene to cells that are utilized in regenerative medicine applications may elongate telomeres and extend cellular life span while avoiding risks that are associated with retroviral or lentiviral vectors. In the present study, adenoviral delivery of pot1-TERT resulted in transient reconstitution of telomerase activity in human smooth muscle cells, as demonstrated by telomeric repeat amplification protocol (TRAP). In addition, human engineered vessels that were cultured using pot1-TERT-expressing cells had greater collagen content and somewhat better performance in vivo than control grafts. Hence, transient delivery of pot1-TERT to elderly human cells may be useful for increasing cellular life span and improving the functional characteristics of resultant tissue-engineered constructs.





Published Version (Please cite this version)


Publication Info

Petersen, Thomas H, Thomas Hitchcock, Akihito Muto, Elizabeth A Calle, Liping Zhao, Zhaodi Gong, Liqiong Gui, Alan Dardik, et al. (2010). Utility of telomerase-pot1 fusion protein in vascular tissue engineering. Cell Transplant, 19(1). pp. 79–87. 10.3727/096368909X478650 Retrieved from https://hdl.handle.net/10161/4616.

This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.



Christopher M. Counter

George Barth Geller Distinguished Professor of Pharmacology

The Counter lab studies the molecular mechanisms that underly to the onset of human cancers, with the goal to prevent cancer initiation or progression.  The lab uses ultra-senstitive sequencing platforms and proteomic-coupled CRISPR/Cas9 screens to elucidate the factors that mold the mutational patterns selected to initiate the process of tumorigenesis.  See https://counter.labs.duke.edu/ for further details.

Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.